Essentially biotech investors assume the role of venture capitalist by funding drug companies with high failure risk.
Is this an opportunity to buy all of those great stocks that “got away from you” in the first quarter run-up, or a portent of nasty things to come?
Apple appeared to be stalling at the $600 level after climbing to this level in an almost vertical chart move.
Our focus in first quarter has been to concentrate only on the best companies going forward and avoid chasing marginal opportunities.
A new Goldman housing index suggests the market is oversold, possibly saying something about REIT investments.
Covestor's Bill DeShurko is getting more conservative with his investment model, as data suggest that "sell in May" is more than just a saying.